Moderna stock upgraded to outperform by Oppenheimer & Co
- Update Date:
- Post Date:
Oppenheimer & Co Analyst, Hartaj Singh, recently upgraded Moderna (MRNA) shares to “Outperform,” with a price target of $142 per share. News of the upgrade has caused shares of the stock to trade over 13% higher on Tuesday. Hartaj Singh joins the Live show to discuss why he upgraded the stock and take a deeper dive into Moderna’s performance going forward. Singh explains that with he expects Covid-19 demand to be bottoming, adding that “if you believe that Covid-19 vaccine sales have… hit a bottom going forward, that essentially funds their pipeline and that pipeline is very important… there are some material catalysts that are coming.” #Moderna #stockmarket #youtube About […]